Study on the Effects of an AMP Challenge on Asthmatic Patients Following Treatment With Fluticasone Propionate

• Status: Completed
• Trial end date: 2005-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Inhaling AMP causes an inflammatory response in the lung. This study will investigate whether 5-days of treatment with fluticasone propionate protects the lung from responding to the AMP in this way.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Fluticasone; Xhance

Criteria

Inclusion Criteria:

• Female of non-childbearing potential

• Using appropriate contraception.

• Mild asthmatic, non (or ex) smokers.

• Has inflammatory response to AMP.

• Otherwise healthy, not using any steroids.

Exclusion Criteria:

• Have a history of life-threatening asthma, defined as an asthma episode, which required intubation and/or was associated with either hypercapnea, respiratory arrest or hypoxia seizures.

• Have a known sensitivity to corticosteroids.

• Have a history of milk protein allergy.

• Test positive at the screening visit for hepatitis B or C or HIV